RxDoctor Payments Data

Padmaja Vittal, MD

Neurology · Winfield, ILNPI 1780818195

Payments from drug & device makers

$69,197in general payments, 2019–2025

Across 113 payments — averaging $612.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$20K
  • MDD US Operations, LLC$15K
  • AbbVie$14K
  • Acorda Therapeutics, Inc$10K
  • Acadia Pharmaceuticals Inc$6K
  • Adamas Pharmaceuticals, Inc.$2K
  • plus $2K from 9 others
$4,000in research payments, 2019–2025

Across 2 payments — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$4K

What the payments were for

  • Consulting fees$7,03511%
  • Speaking & faculty fees$50,92480%
  • Travel & lodging$3,0635%
  • Food & beverage$2,6664%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,197 in reported general payments places this provider in the 85th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$276,063
Medicare patients
226
Services billed
21,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa127$240,555
AustedoDeutetrabenazine26$218,558
GocovriAmantadine Hcl44$203,288
IngrezzaValbenazine Tosylate12$155,605
NuplazidPimavanserin Tartrate17$124,552
InbrijaLevodopa19$95,759
NeuproRotigotine48$95,605
XadagoSafinamide Mesylate11$35,016
Carbidopa-LevodopaCarbidopa/Levodopa741$28,020
Rasagiline Mesylate95$25,473
Carbidopa-Levodopa ErCarbidopa/Levodopa460$17,993
Rivastigmine56$15,257
Entacapone69$14,834
AmantadineAmantadine Hcl227$14,393
Midodrine Hcl168$13,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$155$240,555127 claims
Teva Pharmaceuticals USA, Inc.Austedo$19,707$218,55826 claims
MDD US Operations, LLCGocovri$15,296$203,28844 claims
Neurocrine Biosciences, Inc.Ingrezza$1,275$155,60512 claims
Acadia Pharmaceuticals IncNuplazid$5,698$124,55217 claims
Acorda Therapeutics, IncInbrija$9,697$95,75919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 790 neurology providers in Illinois.

Other neurology in Winfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →